Cilostazol vs pentoksyfilina w leczeniu chorych z chromaniem przestankowym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2017
Słowa kluczowe:
cilostazol, pentoksyfilina, miażdżyca, przewlekłe niedokrwienie kończyn dolnych, chromanie przestankowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Miażdżyca zarostowa tętnic kończyn dolnych w początkowym stadium charakteryzuje się chromaniem przestankowym z dystansem zależnym od stopnia zaawansowania jej zmian. Postęp choroby tętnic obwodowych może prowadzić do zwężeń tętnic, a następnie zamknięcia ich światła. Czynnikami ryzyka rozwoju miażdżycy są: starszy wiek, płeć męska, palenie tytoniu, cukrzyca, dyslipidemia i nadciśnienie tętnicze.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wojtak, A., & Zubilewicz, T. (2017). Cilostazol vs pentoksyfilina w leczeniu chorych z chromaniem przestankowym . Medycyna Faktów , 10(3(36), 270-274. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2138
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bennett P.C., Silverman S., Gill P.S., Lip G.Y.: Ethnicity and peripheral artery disease. QJM 2009; 102: 3-16.
2. Ouriel K.: Peripheral arterial disease. Lancet 2001; 348: 1257-1264.
3. Kim E.S., Wattanakit K., Gornik H.L.: Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve. Clin. J. Med. 2012; 79 (9): 651–661.
4. Bramer S.L., Tata P.N.V., Mallikaarjun S.: Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar. Res. 1997; 14(suppl): S612.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 1992; 20: 900-906.
6. Reilly M.P., Mohler E.R. 3rd: Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 2001; 35: 48-56.
7. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1942-1947.
8. Yoshitomi Y., Kojima S., Sugi T. et al.: Antiplatelet treatment with cilostazol after stent implantation. Heart 1999; 80: 393-396.
9. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. End. Surg. 2007; 33(suppl. 1).
10. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
11. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 2000; 109: 523-530.
12. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 2002; 90: 1314-1319.
13. Lindgarde F., Jelnes R., Bjorkman H. et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.
2. Ouriel K.: Peripheral arterial disease. Lancet 2001; 348: 1257-1264.
3. Kim E.S., Wattanakit K., Gornik H.L.: Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve. Clin. J. Med. 2012; 79 (9): 651–661.
4. Bramer S.L., Tata P.N.V., Mallikaarjun S.: Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar. Res. 1997; 14(suppl): S612.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 1992; 20: 900-906.
6. Reilly M.P., Mohler E.R. 3rd: Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 2001; 35: 48-56.
7. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1942-1947.
8. Yoshitomi Y., Kojima S., Sugi T. et al.: Antiplatelet treatment with cilostazol after stent implantation. Heart 1999; 80: 393-396.
9. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. End. Surg. 2007; 33(suppl. 1).
10. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
11. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 2000; 109: 523-530.
12. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 2002; 90: 1314-1319.
13. Lindgarde F., Jelnes R., Bjorkman H. et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.